



Calibration Certificate

This is to certify that Haematology Analyzer **CelQuant-3 Prime** Instrument Serial. No. **CQP30191216** installed at **IVY Hospital, Nawanshahar** has been calibrated by our engineer on **01-May-2021** with appropriate and sophisticated tools. Below parameters are been calibrated:

This calibration includes preventive maintenance, calibration of all moving parts.

TEST ITEMS AND RESULT

Appearance	OK
Test Speed	OK
Suction sample program	OK
Valve and optical application	OK
Motor & valve	OK
Gain adjustment and red, white MCV test	OK
Sample Volume	OK
Diameter Orifice	OK
Hydraulic Unit	OK
Power Consumption	250V 4A
Fuse check	OK
Power Supply and Earthing	230 Volts and Grounding less then 5V

This Calibration Certificate is Valid Up to **30-April-2022**.

Conclusion: All parameter are within range. The Machine is working properly. (As per Meril terms.)

Engineer Name: **Mr. Amit Kumar**

Designation: **Service Specialist**





614 McKinley Place NE
Minneapolis, MN 55413

Traceability CBC-ST PLUS Hematology Controls

R&D Systems, Inc Hematology Control and Calibrator values are traceable to standard reference methods.

Hematology analyzers in R&D Systems' Quality Assurance Laboratory are whole blood calibrated to values obtained using the following standard reference methods. Whole blood samples drawn from normal, healthy donors are collected in EDTA anticoagulant and analyzed within six hours of collection.

The **White Blood Cell (WBC)** and **Red Blood Cell (RBC)** are analyzed on a Coulter Counter Z series instrument. All counts are corrected for coincidence.

Hemoglobin is measured using the Clinical Laboratory Standards Institute (CLSI) recommended reagent for the hemoglobincyanide (cyanmethemoglobin) method⁽¹⁾. Readings are made at 540 nm in a colorimeter/spectrophotometer calibrated according to CLSI H15-A3 and ICSH recommendations⁽¹⁾.

The **hematocrit** (packed cell volume) is measured using plain glass microhematocrit tubes (not coated with anticoagulant) centrifuged for 5 minutes in a microhematocrit centrifuge according to the CLSI H7-A3 document⁽²⁾. No correction is made for trapped plasma.

Platelets are assayed using a hemocytometer and phase contrast optics.

1. National Committee for Clinical Laboratory Standards (now Clinical Laboratory Standards Institute.) Reference and Selected Procedures for the Quantitative Determination of Hemoglobin in Blood: Approved Standard-Third Edition. NCCLS document H15-A3. Wayne, PA: NCCLS, 2000.
2. National Committee for Clinical Laboratory Standards (now Clinical Laboratory Standards Institute.) Procedure for Determining Packed Cell Volume by the Microhematocrit Method: Approved Standard, NCCLS document H7-A3. NCCLS, Wayne, PA: NCCLS, 2001.

All brands and products are trademarks or registered trademarks of their respective companies.

IVY HOSPITAL

ID:

Date: 01-05-2021 13:33

No. : 217622

Mode: WB

Patient:

Sex: Age: Years

Bed No:

Dept:

Case No:

Item:	Result:	
WBC	0	10 ³ /uL
RBC	0	10 ⁶ /uL
HGB	0	g/dL
HCT	*. **	%
MCV	*. **	fL
MCH	*. **	pg
MCHC	*. **	g/dL
PLT	0	10 ³ /uL
LYM#	*. **	10 ³ /uL
MXD#	*. **	10 ³ /uL
NEUT#	*. **	10 ³ /uL
LYM%	*. **	%
MXD%	*. **	%
NEUT%	*. **	%
RDW-CV	*. **	%
RDW-SD	*. **	fL
PDW	*. **	fL
MPV	*. **	fL
P-LCR	*. **	%
PCT	*. **	%
P-LCC	*. **	10 ³ /uL

IVY HOSPITAL

ID:
Date: 01-05-2021 10:01
No. : 1
Mode: WB
Patient:
Sex: Age: Years
Bed No:
Dept:
Case No:
Item: Result:
WBC 5.7 10³/uL
RBC 3.5 10⁶/uL
HGB ↓9.1 g/dL
HCT ↓31.3 %
MCV 89.3 fL
MCH 26 pg
MCHC ↓29.1 g/dL
PLT 418 10³/uL
LYM# 1.19 10³/uL
MXD# 0.61 10³/uL
NEUT# 3.9 10³/uL
LYM% 20.8 %
MXD% 10.8 %
NEUT% 68.4 %
RDW-CV ↑16.9 %
RDW-SD 50.4 fL
PDW 15.8 fL
MPV 10.3 fL
P-LCR 25.8 %
PCT ↑0.431 %
P-LCC 108 10³/uL

IVY HOSPITAL

ID:
Date: 01-05-2021 10:05
No. : 2
Mode: WB
Patient:
Sex: Age: Years
Bed No:
Dept:
Case No:
Item: Result:
WBC 5.73 10³/uL
RBC 3.51 10⁶/uL
HGB ↓9.2 g/dL
HCT ↓31.3 %
MCV 89.2 fL
MCH 26.2 pg
MCHC ↓29.4 g/dL
PLT 402 10³/uL
LYM# 1.1 10³/uL
MXD# 0.37 10³/uL
NEUT# 4.26 10³/uL
LYM% 19.1 %
MXD% 6.4 %
NEUT% 74.5 %
RDW-CV ↑17 %
RDW-SD 51.3 fL
PDW ↓12.6 fL
MPV 9.7 fL
P-LCR 23.9 %
PCT ↑0.39 %
P-LCC 96 10³/uL

IVY HOSPITAL

ID:
Date: 01-05-2021 10:07
No. : 3
Mode: WB
Patient:
Sex: Age: Years
Bed No:
Dept:
Case No:
Item: Result:
WBC 5.47 10³/uL
RBC 3.51 10⁶/uL
HGB ↓9.2 g/dL
HCT ↓31.1 %
MCV 88.7 fL
MCH 26.2 pg
MCHC ↓29.6 g/dL
PLT 391 10³/uL
LYM# 1.05 10³/uL
MXD# 0.44 10³/uL
NEUT# 3.98 10³/uL
LYM% 19.3 %
MXD% 8 %
NEUT% 72.7 %
RDW-CV ↑16.6 %
RDW-SD 49.5 fL
PDW ↓12.7 fL
MPV 9.8 fL
P-LCR 24.3 %
PCT ↑0.383 %
P-LCC 95 10³/uL

IVY HOSPITAL

ID:
Date: 01-05-2021 10:09
No. : 4
Mode: WB
Patient:
Sex: Age: Years
Bed No:
Dept:
Case No:
Item: Result:
WBC 5.7 10³/uL
RBC 3.58 10⁶/uL
HGB ↓9.4 g/dL
HCT ↓31.9 %
MCV 89.2 fL
MCH 26.3 pg
MCHC ↓29.5 g/dL
PLT 412 10³/uL
LYM# 1.1 10³/uL
MXD# ↑1.2 10³/uL
NEUT# 3.4 10³/uL
LYM% 19.3 %
MXD% ↑21.1 %
NEUT% 59.6 %
RDW-CV ↑17.2 %
RDW-SD 49.5 fL
PDW 16.8 fL
MPV 10.5 fL
P-LCR 26.1 %
PCT ↑0.433 %
P-LCC 108 10³/uL

IVY HOSPITAL

ID:
Date: 01-05-2021 10:11
No. : 5
Mode: WB
Patient:
Sex: Age: Years
Bed No:
Dept:
Case No:
Item: Result:
WBC 5.63 10³/uL
RBC ↓3.49 10⁶/uL
HGB ↓9.2 g/dL
HCT ↓31.1 %
MCV 89.1 fL
MCH 26.4 pg
MCHC ↓29.6 g/dL
PLT 411 10³/uL
LYM# 1.09 10³/uL
MXD# 0.66 10³/uL
NEUT# 3.88 10³/uL
LYM% 19.4 %
MXD% 11.8 %
NEUT% 68.8 %
RDW-CV ↑17 %
RDW-SD 49.5 fL
PDW 16.5 fL
MPV 10.6 fL
P-LCR 26.5 %
PCT ↑0.436 %
P-LCC 109 10³/uL

IVY HOSPITAL

ID:
Date: 01-05-2021 10:14
No. : 6
Mode: WB
Patient:
Sex: Age: Years
Bed No:
Dept:
Case No:
Item: Result:
WBC 5.39 10³/uL
RBC 3.51 10⁶/uL
HGB ↓9.1 g/dL
HCT ↓31.1 %
MCV 88.7 fL
MCH ↓25.9 pg
MCHC ↓29.3 g/dL
PLT 418 10³/uL
LYM# 1.23 10³/uL
MXD# ↑1.12 10³/uL
NEUT# 3.04 10³/uL
LYM% 22.8 %
MXD% ↑20.7 %
NEUT% 56.5 %
RDW-CV ↑16.6 %
RDW-SD 49.5 fL
PDW 16.1 fL
MPV 10.5 fL
P-LCR 26.3 %
PCT ↑0.439 %
P-LCC 110 10³/uL

IVY HOSPITAL

ID:
 Date: 01-05-2021 10:17
 No. : 7
 Mode: WB
 Patient:
 Sex: Age: Years
 Bed No:
 Dept:
 Case No:
 Item: Result:
 WBC 5.6 10³/uL
 RBC 3.5 10⁶/uL
 HGB ↓9.2 g/dL
 HCT ↓31.1 %
 MCV 88.8 fL
 MCH 26.3 pg
 MCHC ↓29.6 g/dL
 PLT 395 10³/uL
 LYM# 1.2 10³/uL
 MXD# 0.8 10³/uL
 NEUT# 3.6 10³/uL
 LYM% 21.5 %
 MXD% 14.2 %
 NEUT% 64.3 %
 RDW-CV ↑16.8 %
 RDW-SD 49.5 fL
 PDW 15.2 fL
 MPV 10.2 fL
 P-LCR 25.2 %
 PCT ↑0.403 %
 P-LCC 100 10³/uL

IVY HOSPITAL

ID:
 Date: 01-05-2021 10:19
 No. : 8
 Mode: WB
 Patient:
 Sex: Age: Years
 Bed No:
 Dept:
 Case No:
 Item: Result:
 WBC 5.56 10³/uL
 RBC 3.5 10⁶/uL
 HGB ↓9.2 g/dL
 HCT ↓31 %
 MCV 88.5 fL
 MCH 26.3 pg
 MCHC ↓29.7 g/dL
 PLT 406 10³/uL
 LYM# 1.21 10³/uL
 MXD# 0.55 10³/uL
 NEUT# 3.8 10³/uL
 LYM% 21.7 %
 MXD% 10 %
 NEUT% 68.3 %
 RDW-CV ↑17.3 %
 RDW-SD 50.4 fL
 PDW ↓12.8 fL
 MPV 9.9 fL
 P-LCR 24.7 %
 PCT ↑0.402 %
 P-LCC 100 10³/uL

IVY HOSPITAL

ID:
 Date: 01-05-2021 10:23
 No. : 9
 Mode: WB
 Patient:
 Sex: Age: Years
 Bed No:
 Dept:
 Case No:
 Item: Result:
 WBC 5.47 10³/uL
 RBC 3.51 10⁶/uL
 HGB ↓9.3 g/dL
 HCT ↓31.1 %
 MCV 88.7 fL
 MCH 26.5 pg
 MCHC ↓29.9 g/dL
 PLT 416 10³/uL
 LYM# 1.16 10³/uL
 MXD# 0.47 10³/uL
 NEUT# 3.84 10³/uL
 LYM% 21.1 %
 MXD% 8.6 %
 NEUT% 70.3 %
 RDW-CV ↑16.8 %
 RDW-SD 49.5 fL
 PDW 16 fL
 MPV 10.3 fL
 P-LCR 25.8 %
 PCT ↑0.428 %
 P-LCC 107 10³/uL

IVY HOSPITAL

ID:
 Date: 01-05-2021 10:29
 No. : 10
 Mode: WB
 Patient:
 Sex: Age: Years
 Bed No:
 Dept:
 Case No:
 Item: Result:
 WBC 5.5 10³/uL
 RBC 3.53 10⁶/uL
 HGB ↓9.3 g/dL
 HCT ↓31.3 %
 MCV 88.8 fL
 MCH 26.3 pg
 MCHC ↓29.7 g/dL
 PLT 393 10³/uL
 LYM# 1.09 10³/uL
 MXD# 0.49 10³/uL
 NEUT# 3.92 10³/uL
 LYM% 19.8 %
 MXD% 8.9 %
 NEUT% 71.3 %
 RDW-CV ↑17 %
 RDW-SD 48.7 fL
 PDW 16.4 fL
 MPV 10.6 fL
 P-LCR 26.8 %
 PCT ↑0.417 %
 P-LCC 105 10³/uL

MERIL DIAGNOSTICS

CELQUANT PRIME
3-PDA HEAMATOLOGY ANALYZER

INSTALLATION QUALIFICATION



Marketed by:
MERIL DIAGNOSTICS.
MUMBAI

I. Approval of the IQ procedure:

Ivy Diagnostic Laboratory and MERIL DIAGNOSTICS are jointly responsible for the installation of the system HEMATOLOGY Analyzer, Model: CELQUANT PRIME, Serial No. CQP30191216 in the clinical lab of **Ivy Diagnostic Laboratory** as per the attached protocol.

Protocol Performed By: MERIL DIAGNOSTICS Representative

Name : **IVY Diagnostic Laboratory** Signature:
Title : **INSTALLATIONQUALIFICATION**
Company : **MERIL DIAGNOSTICS LTD.** Date:03-May-2019

Validation Team from:

Name : SANDEEP SHINDE
Designation : MANAGER- TECHNICAL SERVICE
Department : SERVICE

Customer Authorizations:

Name : Mr Ravi Kumar Signature :
Title : **INSTALLATION QUALIFICATION**
Site : Date:03-May-2019

II. Instructions

1. This document is to be completed at the time the system is shifted to its current location (new) and set up for operation.
2. An authorized representative will check the system and enter the specific data as outlined in the appropriate Installation Qualification. Each result will be noted and dated.
3. Employee of **IVY Diagnostic Laboratory (Mr Ravi Kumar)** will verify each result and sign in the last page. The members of the validation team will carry this out.
4. ALL deviations from normal specification to include any problems with installation will be noted under COMMENTS. All resolution to such problems will also be noted in the COMMENTS section. Additional space is provided at the end of this protocol for the same.

III. Scope

This Installation Qualification protocol will be performed on the Hematology Analyzer, Model CELQUANT PRIME, Serial No. **CQP30191216** located in Inside IVY Hospital Chandigarh road Nawa Shahar. This Protocol will define the documentation that will be used to evaluate the instruments installation in accordance with the manufacture's specifications and intended use. Successful completion of this protocol will verify that the instrument identified has been installed in accordance with the intended usage.

Installation checks will also be performed to verify that the instrument has been installed with proper connections and utilities.

Trained, knowledgeable personnel will perform qualification studies.

Any exceptional conditions encountered during the qualification studies will be identified for review. Exceptional conditions will be investigated and the appropriate course of action determined. All documents will be initialed and dated.

IV. Ancillary Information.

Utilities

Sr.No.	Utility	Yes / No	Verified By	Date
1.	Environmental condition as per requirement: (Ambient range of temperature 15 – 30 °C, relative humidity 45% to 85%, air conditioning facility, non exposure to direct sunlight, non-interference from high frequency radio waves)	Yes / No	Mr Daljeet Singh	3-05-19
2.	Adequate space for installation : for the main unit clearance of around 50 cm from back around 50cm on top and around 50 cm on sides for the main unit)	Yes / No	Mr Daljeet Singh	3-05-19
3.	ALL REAGENTS placed within a distance of 2 meters :	Yes / No	Mr Daljeet Singh	3-05-19
4.	Power Source Requirements* It should have minimum one 5amps plug. It should have proper grounding. In case of online UPS minimum power handling capacity should be minimum 1KVA Line- Neutral voltage:_____	Yes / No	Mr Daljeet Singh	3-05-19
	Line -Earth voltage:_____			
	Neutral-Earth voltage:_____			

c. The instrument has been verified for the following

Sr.No.	Verification	Yes / No	Verified By	Date
1.	Instrument is identified	Yes / No	Mr Daljeet Singh	3-05-19
2.	Manufacturer's specifications are included	Yes / No	Mr Daljeet Singh	3-05-19
3.	Accessories / Consumables are listed	Yes / No	Mr Daljeet Singh	3-05-19
4.	Manufacturer's certificate of Compliance attached	Yes / No	Mr Daljeet Singh	3-05-19

V. Installation Qualification

Equipment Description:

This Hematology Analyzer CELQUANT PRIME is an automated 3-PDA Hematology analyzer for in vitro diagnostic use in clinical laboratories. The CelQuant provides accurate and precise test results for (20) parameters including three histograms.

Instrument identification		Verified by	Date
Equipment Name	3-PDA Hematology	Mr Daljeet Singh	3-05-19
Model	CELQUANT PRIME	Mr Daljeet Singh	3-05-19
Manufacturer	MERIL DIAGNOSTICS	Mr Daljeet Singh	3-05-19
Marketed By	MERIL DIAGNOSTICS	Mr Daljeet Singh	3-05-19
Equipment #	CELQUANT Prime	Mr Daljeet Singh	3-05-19
Serial Number	CQP30191216	Mr Daljeet Singh	3-05-19
Size (in mm)	W 335 X L 475 X H 445	Mr Daljeet Singh	3-05-19
Power	AC 220 V	Mr Daljeet Singh	3-05-19
Frequency	50 – 60 Hz	Mr Daljeet Singh	3-05-19
Power Consumption	Less Than 250 VA	Mr Daljeet Singh	3-05-19

Installation Qualification:

Consumables such as **Standard Accessory** were supplied along with instrument.

Currently a sufficient stock of the same is being maintained Yes No

C. List of Manuals, Certificates and Drawings

MERIL DIAGNOSTICS provides the following with the instrument.

1. Instructions For use
2. User's Guide

D. Change Control Procedure

The instrument will not be altered, enhanced, modified or substituted for another system until a formal Change Control Authorization is approved from MERIL DIAGNOSTICS and **IVY Diagnostic Laboratory**.

E. Maintenance

The instrument listed within this document will be placed under the control of the purchasing institution with respect to proper maintenance procedures as detailed in the Instruction For use.

A trained analyst using the manuals provided with the instrumentation can perform simple maintenance. Upon expiration of the warranty period MERIL DIAGNOSTICS offers several levels of Maintenance Agreements and Performance Testing services to assist you in maintaining **GLP/GMP** compliance. Contacting your local representative and requesting the additional Service Agreement can supply additional information.

Spare Parts

MERIL DIAGNOSTICS strongly recommends the end user maintain a basic of consumable parts onsite to minimize down time due to minor failures. They have provided a list of such consumable parts and the same is also available in the Operator's Manual.

C. Equipment Logs

Title	Location	Verified by	Date

Sample page of the logbook is attached to this document

Effective date:

H. Installation Procedure

(These had been performed at the time of original installation at the initial location)

1. Unpacking Checklist

CELQUANT PRIME Instruction for Use

2. Check Before Installation

CELQUANT PRIME Instruction for Use

3. Grounding

CELQUANT PRIME Instruction for Use

4. Installation Environment & Space

CELQUANT PRIME Instruction for Use

System Certification

Study data has determined that the system described in this document either meets all criteria outlined in this independently Installation Qualification Protocol, or exceptional conditions have been identified and documentation included. Exceptional conditions, if any, have been addressed. The system is ready for specified usage.

Report Performed By : MERIL DIAGNOSTICS Representative

Name : SANDEEP SHINDE.
Title : INSTALLATION QUALIFICATION Signature :
Company : MERIL DIAGNOSTICS. Date :

Customer Authorizations:

Name :
Title : INSTALLATION QUALIFICATION Signature:
Customers name: Date :

- 1) Reagent Check: -
- 2) Printer checked:-
- 3) Analyzer switched ON
- 4) SELF CHECK performed
- 5) RINSE CYCLE completed
- 6) Background limits within acceptable range
- 7) Analysis start time
- 8) Analysis end time
- 9) No. of samples analyzed
- 10) Shut down procedure done
- 11) Analyzer switched OFF at

Recorded by:

Checked by:

MERIL DIAGNOSTICS

3-PDA HEMATOLOGY ANALYZER
CELQUANT PRIME

OPERATIONAL
QUALIFICATION

Marketed by:
MERIL DIAGNOSTICS

I. Approval of the OQ procedure:

IVY Diagnostic Laboratory and **MERIL DIAGNOSTICS** are jointly responsible for operational check of the **HEMATOLOGY Analyzer**, Model: **CELQUANT PRIME** serial No. **CQP30191216** in the clinical lab of Inside ivy hospital, Chandigarh road, Nawa shahar , Punjab as per protocol attached.

Protocol Performed by: **MERIL DIAGNOSTICS Representative**

Name	:	Mr Daljeet Singh	Signature:
Title	:	OPERATIONAL QUALIFICATION	Date: 03-May-2019
Company	:	MERIL DIAGNOSTICS.	
Designation	:	Area Service Manager	
Department	:	SERVICE	

Customer Authorization:

Name	:	Mr Ravi Kumar	Signature:
Title	:	OPERATIONAL QUALIFICATION	Date: 03-May-2019
Site	:		

II. Instructions

5. The MERIL DIAGNOSTICS representative will check each module and enter the specific data as described in the Operational Qualification. Each result will be noted and dated.
6. Employee of the **IVY Diagnostic Laboratory, (Mr Ravi Kumar)** will verify each result and sign in the last page. The member/s of the validation team will be responsible for the same.
7. Any deviations from the acceptance criteria detailed in this document will be noted in the _____(COMMENT) section of the OQ protocol. All resolution to such problems will also be noted in the _____(COMMENTS)section, and must be resolved prior to issuance of a SYSTEM CERTIFICATION. This will be an additional cost to the purchasing institution IVY Diagnostic Laboratory. However this additional cost will be waived when this test is conducted at time of initial performance check of new instruments.
8. Any test data, which does not meet the specified acceptance criteria, will be submitted to the appropriate laboratory personnel for solution. All steps taken subsequently will be documented.

III. Scope

This Operational Qualification protocol will be performed on the Hematology Analyzer, CELQUANT PRIME, Serial No.CQP30191216 located in **IVY Diagnostic Laboratory, Nawa Shaher, Punjab** This Protocol will define the documentation that will be used to evaluate the instruments installation in accordance with the manufacturer's specifications and intended use. Successful completion of this protocol will verify that the instrument identified is performing in accordance with the intended usage.

Trained, knowledgeable personnel will perform qualification studies.

Any exceptional conditions encountered during the qualification studies will be identified for review. Exceptional conditions will be investigated and the appropriate course of action determined. All documents will be initialed and dated.

IV. Operational Qualification

a. Instrument Identification

Verified Date

1. Model Name	CELQUANT PRIME	03-5-2019
2. Serial Number	CQP30191216	03-5-2019

b. Following is a list of tests to be performed and verified and demonstrated to user:

<u>Test No.</u>	Test Name	Test Purpose	Verified Date
1.	Vacuum Pump	To verify pressure & Vacuum generation	03-05-2019
2.	Arm Motor	Capacity of performing Arm functions.	
3.	Hgb Lamp	To check HGB result	
4.	Solenoid valve	To test & verify function of Solenoid valves	
5.	Display Unit	To test & verify Screen & Touch	

c. Operational Testing

Test 1

Test Name : Vacuum Pump.

Purpose : To test Vacuum Pump

Method : Service Menu

PARAMETER PASS FAIL

Parameter values for verification : Vacuum PUMP

Test 2

Test Name : Arm Motor

Purpose : To test Arm Motor function

Method : Service Menu

PARAMETER PASS FAIL

Parameter values for verification : Arm Motor

Test 3

Test Name : Hgb Lamp

Purpose : To test Hgb Gain.

Method : Diagnostic Menu

PARAMETER PASS FAIL

Parameter values for verification : Hgb Lamp Test

Test 4

Test Name : Solenoide Valve

Purpose : To test the Solenoide valves operation.

Method : Diagnostic Menu

PARAMETER PASS FAIL

Parameter values for verification : Solenoide Valve Test

Test 5

Test Name : Display

Purpose : To test functioning of touch and screen functioning

Method : Manual

PARAMETER PASS FAIL

Parameter values for verification : Display Test

Operational Procedure

a. Certificate of Training

1. Technician Training

This certifies that the technicians listed below have received basic user training in the following categories for the system described in this Installation Qualification.

Mr.Ravi Kumar who is certified by MERIL DIAGNOSTICS Ltd has conducted the training.

Sr.No.	Training Program	Initials	Date
1.	Instrument Setup		
2.	System Operation		
3.	Basic Troubleshooting & Maintenance		

2. Operator Training

The users responsible for the operation of this instrument will be trained in the proper usage of the system. Training will focus on the basic operation and maintenance of the system. The training of the operators will be documented and the training records will be filed as indicated below :

Sr.No.	Operators	Location	Initials	Date

Customer SOP

Title	Number	Revision #	Effective Date	Location	Verified By	Date
Operating Procedure		NA				

VII. System Certification

Study data has determined that the system described in this document either meets all criteria outlined in this Operational Qualification Protocol, or exceptional conditions have been identified and documentation included. Exceptional conditions, if any, have been addressed. The system is ready for specified usage.

Report Performed By : Meril Diagnostics **Representative**

Name : SANDEEP SHINDE

Title : OPERATIONAL QUALIFICATION Signature:

Company: MERIL DIAGNOSTICS LTD. Date :03-05-2019

Designation: MANGER-TECHNICAL SERVICE.

Customer Authorizations:

Name : Mr Ravi Kumar

Title : OPERATIONAL QUALIFICATION Signature:

Company: Date :03-05-2019

MERIL DIAGNOSTICS

CELQUANT PRIME

3-PDA HEMATOLOGY ANALYZER

PERFORMANCE
QUALIFICATION

Marketed by:

MERIL DIAGNOSTICS

MUMBAI

I. Approval of the PQ procedure :

Both **IVY Diagnostic Laboratory** and **MERIL DIAGNOSTICS** are jointly responsible for conducting the **Performance Check** of the **Hematology Analyzer, CELQUANT PRIME Serial No.CQP30191216** in the clinical lab of **IVY Diagnostic Laboratory** as per the attached protocol.

Protocol Performed By : **MERIL DIAGNOSTICS Representative**

Name	:	Mr Daljeet Singh	Signature :
Title	:	PERFORMANCE QUALIFICATION	Date :03-05-2019
Company	:	MERIL DIAGNOSTICS	
Designation	:	Area Service Manager.	
Department	:	SERVICE	

Customer Authorizations:

Name	:	Mr Ravi Kumar	Signature :
Title	:	PERFORMANCE QUALIFICATION	Date :03-05-19
Site	:		

II. Instructions

9. An authorized **MERIL DIAGNOSTICS** representative will check for the performance of the instrument and enter the specific data as outlined in the Performance Qualification. Each result will be noted and dated.
10. Performance checks on a regular basis described in the Further Performance Checks (vide-infra) will be responsibility of the customer's personnel.
11. Employee of **IVY Diagnostic Laboratory** will verify each result and sign in the last page. The members of the validation team will carry this out.
12. ALL deviations from the acceptance criteria detailed in this document will be noted in the COMMENTS section at the end of each PQ protocol. All resolution to such problems will also be noted in the COMMENTS section, and must be resolved prior to issuance of a SYSTEM CERTIFICATION. These will be an additional cost to the purchasing institution **IVY Diagnostic Laboratory**. However this additional cost will be waived when this test is conducted at time of initial performance check of new instruments.

c. Performance Testing

Test 1

Test Name: Precision Testing

Purpose: To comply with specification and find out deviation if any. If required to apply correction

Method: To run normal sample 06 times consecutively and identify SD, CV and to establish that it lies as per the manufacturer's specs. To omit first run and to consider rest 05 runs and to calculate SD & CV

Run sequence	WBC	RBC	HGB	HCT	MCV	PLT
2						
3						
4						
5						
Mean						
SD						
CV%						
Status PASS/FAIL						

c. Accuracy Testing

Test 2

Test Name : Accuracy Check

Purpose: Ability to Process Samples

Method: To Run Normal Level control five times

Acceptance Criteria: Each of the results obtained above should be within the range as specified in the control chart.

Parameters Values for Verification: Control Level: "N"

Lot no:

Exp dt:

WBC Count:

Sr. No.	Control Values	Results Obtained	Pass	Fail
1				
2.				
3.				
4.				
5.				

RBC Count:

Sr. No.	Control Values	Results Obtained	Pass	Fail
1				
2.				
3.				
4.				
5.				

HGB:

Test	Control Values	Results Obtained	Pass	Fail
------	----------------	------------------	------	------

1.				
2.				
3.				
4.				
5.				

MCV:

Test	Control Values	Results Obtained	Pass	Fail
1.				
2.				
3.				
4.				
5.				

Platelet Count:

Test	Control Values	Results Obtained	Pass	Fail
1.				
2.				
3.				
4.				
5.				

C. List of Manuals, Certificates and Drawings

MERIL DIAGNOSTICS provides the following with the instrument.

- 3. Instruction For Use
- 4. User's Guide

D. Change Control Procedure

The instrument will not be altered, enhanced, modified or substituted for another system until a formal Change Control Authorization is approved from **MERIL DIAGNOSTICS** and **IVY Diagnostic Laboratory**.

E. Maintenance

The instrument listed within this document will be placed under the control of the purchasing institution with respect to proper maintenance procedures.

A trained analyst using the manuals provided with the instrumentation can perform simple maintenance. Upon expiration of the warranty period MERIL DIAGNOSTICS offers several levels of Maintenance Agreements and Performance Testing services to assist you in maintaining **GLP/GMP** compliance. Contacting your local representative and requesting the additional Service Agreement can supply additional information.

VII. System Certification

Study data has determined that the system described in this document either meets all criteria outlined in this Performance Qualification Protocol, or exceptional conditions have been identified and documentation included. Exceptional conditions, if any, have been addressed. The system is ready for specified usage.

Report Performed By : MERIL DIAGNOSTICS Representative

Name : SANDEEP SHINDE Signature:
DESIGNATION: MANAGER-TECHNICAL SERVICE
Title : PERFORMANCE QUALIFICATION
Company : MERIL DIAGNOSTICS Date :03-05-19

Customer Authorizations:

Name : Mr Ravi Kumar Signature :
DESIG : Lab Manager
Title : PERFORMANCE QUALIFICATION
Company : Date :03-05-19